Navigation Links
For Treatment of Irritable Bowel Syndrome, Linaclotide Will Emerge as the Market Leader and Will Achieve Blockbuster Status in 2019

BURLINGTON, Mass., Dec. 16, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its superb efficacy, acceptable safety profile and anticipated launch in all major markets, Ironwood/Forest/Almirall/Astellas's linaclotide will emerge as the market leader for the treatment of irritable bowel syndrome (IBS). In 2019, linaclotide will garner blockbuster sales of $1.1 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Although Sucampo/Takeda/Abbott's Amitiza was the IBS drug market leader in 2009, the drug's limited efficacy, loss of patent protection and competition from linaclotide will cause Amitiza's sales to drop sharply through 2019.

The findings from the Pharmacor topic entitled Irritable Bowel Syndrome, which will publish later this month, reveal that the overall IBS drug market will expand at a 14 percent annual rate from 2009 to 2019, owing to the market entry of much-needed first-in-class therapies.

The findings also reveal that, because of the heterogeneity of IBS and the high rate of generic penetration, the IBS therapy market is highly fragmented and underserved. The lack of prescription therapies that can address more than one symptom of the disease means that physicians and patients resort to using multiple drugs, many of which are inadequate at controlling motility or pain symptoms associated with IBS. Additionally, owing to the combination of high prevalence and low diagnosis rates, substantial commercial potential exists for the development of drugs that target this indication.  

"IBS is a highly prevalent chronic condition in the world's major pharmaceutical markets, but the lack of a biochemical or histological marker for positive diagnosis and incomplete understanding of the disease's pathophysiology and etiology have resulted in low diagnosis and treatment rates," said Decision Resources Analyst Iva Holder, Ph.D. "The limited number of efficacious treatment options suggests significant opportunity for new IBS therapies."

About Decision ResourcesDecision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Receives FDA Clearance for the CyberKnife® Systems Lung Optimized Treatment
2. Use of Vitamin K Antagonists in the Treatment of Atrial Fibrillation is Driven by the Availability of an Oral Formulation, Cost and Widespread Inclusion on Guidelines and Formularies
3. MHRA Issues Notice of Acceptance for Phase 3 Trial of GALNS for the Treatment of MPS IVA
4. ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
5. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
6. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
7. Physiotherapy Associates Announces New Multiple Sclerosis Specialty Treatment Program
8. Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020
9. Cancer Treatment Centers Oncology Information System Options Expand with New MOSAIQ Connectivity
10. Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020
11. Reportlinker Adds Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020
Post Your Comments:
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... recent 2015 American Dental Association meeting in Washington D.C. revolved around the fact that ... patient’s overall health. The talk stressed the link between periodontal disease (more commonly referred ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the health care in America. As people age, more care is needed, especially ... are rising, and medical professionals are being overworked. The forgotten part of this ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... toilets were," said an inventor from Hillside, N.J. "Many people catch diseases simply ... so that individuals will always be protected from germs." , He developed the ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):